Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Enrolling by invitation × Dexamethasone × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Completed 52 Terminated 33 Recruiting 32 Active not recruiting 16 Unknown 10 Withdrawn 9 Not yet recruiting 4 Suspended 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Lenalidomide 2 irinotecan sucrosofate 1 enzalutamide 1 Ruthenium-106 1 Radiotherapy 1 Melphalan 1 Mannitol 1 Leukocyte Count 1 Irinotecan 1 Folfox protocol 1 Dexamethasone 1 Cyclophosphamide 1 Carboplatin 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

HuniLife Biotechnology, Inc.

Phase 1/2 Enrolling by invitation

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡